Nov 08, 2023 7:05am EST Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Oct 31, 2023 8:00am EDT Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Oct 31, 2023 8:00am EDT Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Oct 25, 2023 8:06am EDT Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Oct 23, 2023 4:15am EDT Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Sep 11, 2023 8:00am EDT Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Aug 03, 2023 1:24pm EDT Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Jun 01, 2023 3:29pm EDT Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
